What's Happening?
Anixa Biosciences, a biotechnology company focused on cancer treatment and prevention, announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center, will present the status of their ovarian cancer CAR-T therapy
Phase 1 trial at the Society of Gynecologic Oncology Annual Meeting on Women's Cancer. The meeting, scheduled for April 10-13, 2026, in San Juan, Puerto Rico, is a significant event for professionals in gynecologic oncology. The trial involves lira-cel, a therapy targeting the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. This receptor is selectively expressed on ovarian cells and certain cancer cells, making it a promising target for treatment. The trial is enrolling women with recurrent ovarian cancer who have not responded to at least two prior therapies.
Why It's Important?
The presentation of Anixa's CAR-T therapy trial at a major oncology meeting highlights the potential of innovative treatments in the fight against ovarian cancer, a disease with limited treatment options. The use of chimeric endocrine receptor-T cell (CER-T) technology represents a novel approach in cancer immunotherapy, potentially offering new hope for patients with recurrent ovarian cancer. This development underscores the importance of continued research and collaboration between biotechnology companies and leading research institutions like Moffitt Cancer Center. Successful outcomes from this trial could pave the way for new therapies that improve survival rates and quality of life for patients with ovarian cancer.
What's Next?
Following the presentation, Anixa Biosciences will likely continue to monitor and report on the progress of the Phase 1 trial. The results could influence future clinical trials and regulatory decisions regarding the approval and use of lira-cel in treating ovarian cancer. Stakeholders, including patients, healthcare providers, and investors, will be closely watching for updates on the trial's outcomes and any potential advancements in the therapy's development.
